We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

224 hedge funds and large institutions have $2.68B invested in Amicus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 86 increasing their positions, 57 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 26

65% more call options, than puts

Call options by funds: $9.49M | Put options by funds: $5.74M

51% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 57

22% more capital invested

Capital invested by funds: $2.2B → $2.68B (+$482M)

9% more funds holding

Funds holding: 205224 (+19)

0.35% more ownership

Funds ownership: 107.63%107.98% (+0.35%)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

Holders
224
Holders Change
+19
Holders Change %
+9.27%
% of All Funds
4.41%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.12%
New
50
Increased
86
Reduced
57
Closed
26
Calls
$9.49M
Puts
$5.74M
Net Calls
+$3.74M
Net Calls Change
-$1.35M
Name Holding Trade Value Shares
Change
Change in
Stake
BAM
151
Blueshift Asset Management
New Jersey
$221K +$96.5K +10,539 +87%
AIP
152
Ameritas Investment Partners
Nebraska
$218K +$9.91K +1,083 +5%
KFA
153
Kelleher Financial Advisors
New York
$208K +$196K +21,450 New
BCM
154
Bayesian Capital Management
New York
$197K -$25.6K -2,794 -12%
SAM
155
Shell Asset Management
Netherlands
$186K -$3.98K -435 -2%
Zurich Cantonal Bank
156
Zurich Cantonal Bank
Switzerland
$181K +$33.6K +3,676 +25%
NIT
157
NumerixS Investment Technologies
British Columbia, Canada
$181K +$170K +18,600 New
Canada Life
158
Canada Life
Manitoba, Canada
$175K +$40.7K +4,450 +33%
CANY
159
Caxton Associates (New York)
New York
$174K +$164K +17,870 New
AAMU
160
Amundi Asset Management US
Massachusetts
$170K
VWM
161
Vigilare Wealth Management
Arizona
$165K +$169K +18,500 New
CC
162
Centiva Capital
New York
$161K +$50.3K +5,490 +50%
AI
163
Atom Investors
Texas
$159K +$150K +16,362 New
First Trust Advisors
164
First Trust Advisors
Illinois
$149K -$782K -85,388 -85%
BOPW
165
Brandywine Oak Private Wealth
Pennsylvania
$142K +$134K +14,676 New
SG Americas Securities
166
SG Americas Securities
New York
$140K -$1.56M -170,038 -92%
Mitsubishi UFJ Asset Management
167
Mitsubishi UFJ Asset Management
Japan
$136K +$22.4K +2,452 +20%
HS
168
Haafor (Singapore)
Singapore
$133K +$125K +13,609 New
Ensign Peak Advisors
169
Ensign Peak Advisors
Utah
$129K +$121K +13,177 New
Verition Fund Management
170
Verition Fund Management
Connecticut
$124K -$590K -64,494 -83%
Rockefeller Capital Management
171
Rockefeller Capital Management
New York
$122K -$18.8K -2,050 -14%
TRCT
172
Tower Research Capital (TRC)
New York
$120K +$112K +12,246 +12,246%
NICM
173
Neo Ivy Capital Management
New York
$111K +$104K +11,348 New
GTCM
174
Gyon Technologies Capital Management
New Jersey
$110K +$103K +11,252 New
CA
175
Calton & Associates
Florida
$108K +$3.77K +412 +4%

FOLD Hedge Fund Activity: Q4 2019 in Review

224 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2019, worth a combined $2.68B — up 22% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new FOLD positions and 26 closed out — a net gain of 24 holders — while 86 added to existing stakes and 57 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $27.4M. The largest seller was Deutsche Bank, cutting an estimated $36.7M.

  • 224 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2019, up from 205 in Q3 2019.
  • Funds reported $2.68B of Amicus Therapeutics stock for Q4 2019, up 22% quarter-over-quarter.
  • 50 funds opened new Amicus Therapeutics positions in Q4 2019 and 26 closed out, a net change of +24 holders.
  • The largest Amicus Therapeutics buyer in Q4 2019 was JP Morgan Chase, an estimated $27.4M added.
  • The largest Amicus Therapeutics seller in Q4 2019 was Deutsche Bank, an estimated $36.7M sold.

Based on aggregated 13F filings for Q4 2019.